Regulatory News
Thursday, January 5, 2017
BRIEF-ClinicalTrials.gov says Seattle Genetics' study of brentuximab vedotin combined with nivolumab suspends enrollment
* Seattle Genetics' study of brentuximab vedotin combined
with nivolumab for relapsed or refractory hodgkin lymphoma
suspends enrollment
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment